Evaluating amyloid burden in cardiac amyloidosis using bone scintigraphy
Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy for the Follow-up of Patients With Transthyretin Amyloidosis Treated With Tafamidis
This study is testing a new way to measure amyloid buildup in the hearts of people with transthyretin cardiac amyloidosis to see if it can help doctors better track the disease and improve treatment outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | GCS Ramsay Santé pour l'Enseignement et la Recherche Academic / other |
| Locations | 1 site (Lille) |
| Trial ID | NCT04849754 on ClinicalTrials.gov |
What this trial studies
This study focuses on improving the assessment of cardiac amyloidosis by utilizing quantitative analysis methods of bisphosphonate scintigraphy. It aims to provide a more accurate evaluation of amyloid burden and patient prognosis compared to traditional semi-quantitative methods. The study will involve patients diagnosed with transthyretin cardiac amyloidosis, and will assess the effectiveness of bone scintigraphy in monitoring disease progression over time. By enhancing diagnostic capabilities, the study seeks to contribute to better patient management and treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy.
Not a fit: Patients with systemic AL amyloidosis or those under legal protection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and treatment strategies for patients with cardiac amyloidosis.
How similar studies have performed: While there is ongoing research in the field, this specific quantitative approach to evaluating amyloid burden in cardiac amyloidosis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient, male or female, over 18 years of age * Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy * Patient with signed consent Exclusion Criteria: * Patients with systemic AL amyloidosis * Protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision * Pregnant or breastfeeding woman
Where this trial is running
Lille
- Hôpital privé Le Bois — Lille, France (Recruiting)
Study contacts
- Principal investigator: Fredric MOUQUET — Hôpital Privé Le Bois
- Study coordinator: Frederic MOUQUET
- Email: fmouquet@ovh.fr
- Phone: 0642377375
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.